Validating surrogates for cerebral blood flow in Alzheimer’s Disease.

Takeaway

  • The early phases (first 2 min), 18F-FDG (FDG) PET, and the delivery rate R1 of 18F-AV45 PET were demonstrated to be valid surrogate markers for cerebral blood flow (CBF) in Alzheimer’s disease (AD) and were sensitive markers for disease severity in comparison to early-phase 18FAV45 PET.

Why this matters

  • The dual biomarker position emission tomography (PET) is of clinical interest for AD because they can provide information on cerebral blood flow and amyloid-β deposition and assess how they change with disease severity.